Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance
The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufa...
The drugmaker said it is reviewing legal options including filing an appeal against the court order.
Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.
Jardiance is top-selling drug for BI in India.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.